EZZ Life Science - Public Comps and Valuation Multiples

EZZ Life Science Overview

About EZZ Life Science

EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.

Founded

2015

HQ

Employees

n/a

Website

ezzlife.com.au

Sectors

Genomics & Personalized Medicine
Health & Beauty
BioTech
DeepTech

Financials

LTM Revenue $43.5M

Last FY EBITDA $7.2M

EV

$81.7M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

EZZ Life Science Financials

As of September 2025, EZZ Life Science reported last 12-month revenue of $43.5M.

In the same period, EZZ Life Science achieved $4.4M in LTM net income.

See EZZ Life Science valuation multiples based on analyst estimates

EZZ Life Science P&L

In the most recent fiscal year, EZZ Life Science reported revenue of $43.5M and EBITDA of $7.2M.

EZZ Life Science expects next 12-month revenue of XXX and NTM EBITDA of XXX

See EZZ Life Science valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$43.5M	XXX	$43.5M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$32.3M	XXX	XXX	XXX
Gross Margin	n/a	XXX	74%	XXX	XXX	XXX
EBITDA	n/a	XXX	$7.2M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	17%	XXX	XXX	XXX
EBIT	n/a	XXX	$6.5M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	15%	XXX	XXX	XXX
Net Profit	$4.4M	XXX	$4.4M	XXX	XXX	XXX
Net Margin	10%	XXX	10%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for EZZ Life Science including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $43.5M. In the most recent fiscal year, EZZ Life Science achieved $43.5M in revenue and $7.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$43.5M	Analyst estimates available to subscribers	$43.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$32.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	74.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$7.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	16.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	n/a	Analyst estimates available to subscribers	$6.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	14.8% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$4.4M	Analyst estimates available to subscribers	$4.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	10.1% net profit margin	Analyst estimates available to subscribers	10.1% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for EZZ Life Science

This financial data table provides comprehensive performance metrics for EZZ Life Science, a company based in Australia. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

EZZ Life Science generated $43.5M in revenue over the last twelve months.
Net income over the last twelve months reached $4.4M.

Fiscal Year Performance

In the most recent fiscal year, EZZ Life Science reported $43.5M in total revenue.
Fiscal year EBITDA was $7.2M.
The company maintained a gross profit margin of 74.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 16.6%.
Net profit margin reached 10.1% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for EZZ Life Science. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

EZZ Life Science Stock Performance

EZZ Life Science has current market cap of AUD 146M (or $95.1M), and EV of AUD 126M (or $81.7M).

Market Cap Evolution

EZZ Life Science Stock Data

As of October 24, 2025, EZZ Life Science's stock price is AUD 3 (or $2).

See EZZ Life Science trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$81.7M	$95.1M	XXX	XXX	XXX	XXX	$0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

EZZ Life Science Valuation Multiples

EZZ Life Science's trades at 1.9x EV/Revenue multiple, and 11.7x EV/EBITDA.

See valuation multiples for EZZ Life Science and 15K+ public comps

EZZ Life Science Financial Valuation Multiples

As of October 24, 2025, EZZ Life Science has market cap of $95.1M and EV of $81.7M.

Equity research analysts estimate EZZ Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

EZZ Life Science has a P/E ratio of 21.7x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$95.1M	XXX	$95.1M	XXX	XXX	XXX
EV (current)	$81.7M	XXX	$81.7M	XXX	XXX	XXX
EV/Revenue	1.9x	XXX	1.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	11.7x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	12.8x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	21.7x	XXX	21.4x	XXX	XXX	XXX
EV/FCF	n/a	XXX	25.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get EZZ Life Science Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

EZZ Life Science Margins & Growth Rates

EZZ Life Science's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

EZZ Life Science's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

EZZ Life Science's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for EZZ Life Science and other 15K+ public comps

EZZ Life Science Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	16%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	48%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	59%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial